Listen to article
6:41Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
There are few things in the financial world quite as entertaining as an activist investor. They arrive on the scene like a rather cross, well-funded bloke turning up at a garden party to complain about the state of the hedges. They don’t whisper, they shout. And when they start shouting, as Engine Capital is now doing at life sciences firm Avantor, you’d be wise to listen. To me, it’s not just about one company. It’s a signal, a tremor that suggests the entire ground beneath a rather overlooked sector could be about to shift.
For those of you whose eyes glaze over at the term ‘life sciences supply chain’, let me put it simply. Think of the great pharmaceutical and biotech giants as the celebrity chefs of modern medicine. Well, companies like Avantor, Thermo Fisher, and Danaher are the ones who sell them the pots, pans, and fantastically expensive ovens. They provide the essential, unglamorous kit that makes all the life-saving innovation possible. They are the plumbers of the medical world, and while you never think about them, everything grinds to a halt when they’re not there.
So why is Engine Capital making such a fuss now? Because, in their view, and I’m inclined to agree, these critical businesses have been trading at a discount. The market, obsessed with flashy tech and consumer brands, has rather forgotten about the companies that build the industry’s backbone. They’ve been hiding in plain sight, churning out steady revenues while being valued as if they were selling novelty teacups.
An activist push like this is often the catalyst that forces everyone else to open their eyes. When a firm like Avantor is publicly branded as undervalued and a prime target for a sale, it doesn't just put its own management on notice. It sends a jolt through the entire sector. Competitors start looking over their shoulders, potential buyers get their calculators out, and institutional money that had previously ignored the space suddenly takes a keen interest. It’s the financial equivalent of turning the lights on in a dusty room and realising some of the old furniture is actually priceless antique.
Now, trying to bet on whether Avantor itself will be sold is a bit of a mug’s game. These things can get tangled in boardroom politics and regulatory knots for ages. The smarter way to think about this, I believe, is to look at the potential ripple effect. If one major player is in play, the logic of consolidation suggests others might follow. The whole sector could be poised for a re-rating.
This is where a thematic approach makes a great deal of sense. Instead of trying to pick the one horse that might win the race, you can gain exposure to the whole stable of runners. It’s the core idea behind investment baskets like the Activist Sparks Life Science Shakeup collection, which understands that the opportunity isn't just one company, but the disruption across an entire industry. It’s about investing in the earthquake, not just a single trembling building.
Of course, let’s not get carried away. Investing is never a one way street, and there are no guarantees here. Engine Capital might fail entirely, and the excitement could fizzle out as quickly as it began. Mergers and acquisitions are notoriously difficult to predict, and regulators have become increasingly wary of letting big fish swallow other big fish. Furthermore, these companies face constant pressure on pricing from healthcare systems trying to rein in costs.
But even with those risks, the fundamental picture remains compelling. These are established, profitable companies providing essential services in a market that, let’s face it, isn’t going away. People will always get sick, and we will always need new medicines. The companies that supply the tools for that research have a defensive quality that is rather attractive in today’s choppy economic waters. The activist intervention is simply the spark, the real fuel is the underlying, and perhaps undervalued, importance of the entire sector.
View the full Basket:Activist Sparks Life Science Shakeup
View the full Basket:Activist Sparks Life Science Shakeup
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
